Analysis of volatile metabolites in biological fluids as indicators of prodromal disease condition by Zlatkis, A.
  
 
 
N O T I C E 
 
THIS DOCUMENT HAS BEEN REPRODUCED FROM 
MICROFICHE. ALTHOUGH IT IS RECOGNIZED THAT 
CERTAIN PORTIONS ARE ILLEGIBLE, IT IS BEING RELEASED 
IN THE INTEREST OF MAKING AVAILABLE AS MUCH 
INFORMATION AS POSSIBLE 
https://ntrs.nasa.gov/search.jsp?R=19820010985 2020-03-21T10:20:25+00:00Z
(NASA-CR-167513) ANALYSIS 07 VOLATILE 	 002-18859
RETABOLITES IN BIOLOGICAL FLUIDS AS
1061CATORS OF PAODRONAL DISEASE CONDITION
Final Report (Houston Univ.) 25 p	 Unclas
HC A02/KF 1101	 CSCL 06B G3/52 09155
ANALYSIS OF VOLATILE METABOLITES IN BIOLOGICAL FLUIDS
AS INDICATORS OF PRODROMAL DISEASE CONDITION
Contract No: NAS 9-15882
FINAL REPORT
.,......,
January, 1952
Principal Investigator: Dr. A. Zlatkis
Al
Department of Chemistry
Univerpity of Houston
Houston, Texas
r;
To maintain a healthy population with a fully active life
span, it is important that methods be developed for the early
detection of disease. The recognition of the complexity of the
diagnosis of disease has led to a demand from the physician for
more detailed information on the chemical composition of essen-
tial fluids and body tissues. The concept of profiling as a
diagnostic aid extends from the asumption of carrod (1), made in
1908, that pathological states could possibly be reflected in
characteristic changes in the concentration of certain consti-
tuents in biological fluids. This assumption also forms the
cornerstone of Paulirg's concept of "orthomolecular medicine"
(2,3) .
Of particular interest to this laboratory has been the
development of techniques for the analysis of the organic volatile
fract.o't from biological fluids. The volatile profile cannot be
defined as a single class of substances, rather it is a broad
spectrum of materials of different polarities characterised by
having a boiling-point in the Low to medium range (up to approxi-
mately 3000C) and the fact that the compounds are suitable for
gas chromatography without derivatization. The organic volatile
profiles are very complex mixtures of metabolic byproducts,
intermediates, and terminal products of enzymatic degradations
rnmposed mainly of alcohols, ketones, aldehydes, pyrazines,
lfides, isothiocyanates, pyrroles, and furans.
The concentration of organic volatiles in biological fluids
vers a wide range with many important components present at
ace levels. The complexity of the organic volatile fraction re-
a
2quires the use of Capillary columns for their separation. The
nature of biological fluids prevents the use of direct chromato-
graphic injection techniques as, apart from the sensitivity prob-
lem, the large amounts of high relative molecular mass biological
molecules and inorganic salts destroy the capillary columns used
for the separation. The low sample capacity of capillary columns
limits the volume injected to a few tenths of a microlitre, which
is a problem in trat.,.e analysis unless isolation of the organic
volatile fraction from the biological matrix can be performed in
a selective manner.
No single sampling procedure is ideal for the isolation of
the organic volatile fraction from all biological fluids. The
headspace sampling technique (Figure 1) with condensation of the
e ganic volatiles in a cryogenic trap (3-7) or by collection on
a porous polymer (8-21) is well suited to the analysis of 24-h.
human urine samples where sample volume is not a problem. The
minimum sample volume for profile analysis is 25.0 ml of urine
because of the low efficiency of removing the organic volatiles
from the matrix arising from the slow equilibration between organic
molecules in the urine sample and the gas phase above the fluid.
Sampling times are long and the profile obtained is representative
of the concentration of the volatiles in the sample rather than
a complete purging of the volatiles. Headspace techniques have
also been used for the analysis of serum (22-24), tissue homoge-
nates (22,25), and spinal fluid (12) where sample volume limita-
tions are a problem in developing adequate profiles for diagnostic
purposes. For the analysis of small sample volumes (1-5 ml) gas-
3phase stripping techniques can be employed (261, but the same
observations as applied to the dynamic headspace methods are also
true of this technique. When applied to serum, gas-phase strip-
ping techniques (Figure 2) failed to reveal the complete complexity
of the organic volatile fraction and the sample requirement of the
order of a few milliliters was too high for some problems, e.g.,
animal studies with small. rodents (22, 26). This prompted the
investigation of solvent extraction techniques as a means of iso-
lating the organic volatile fraction from urine (27-29), plasma
(26, 29 1
 30), tissue homogenates (26), blood (31), breast milk
and amAiotic fluid (29)
	 The profiles obtained by solvent extrac-
tion are selective as the extraction efficiency is dependent on
the partition coefficient of the solutes and the area of contact
between the solvent and sample. The limitations of the solvent
extraction technique are the need for very pure solvents, evapora-
tion of the solvent is usually accompanied by a loss of compounds
r
of low boiling-point and the fact that no solvent will extract to
Equal extents the complex range of volatile compounds present in
i	 biological, fluids. The transevaporator sampling apparatus has
been used for the analysis of urine, serum, amniotic fluid, breast
i
milk, and saliva with a sample volume requirement of 5-500 pl.
SAMPLE CONCENTRATION WITH THE TRANSEVAPORATOR
The transevaporator was designed for the micro analysis of
trace vo',atiles in an aqueous solution by selective concentration
r	 and removal of water. The apparatus is shown in Figure 3 and
can be used to provide in two steps both a modified headspace and
an extraction profile on a single sample ranging from 5-500 pl.
The sample in a syringe is slowly injected on to the Porasil E
;r
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micro-column, which is then attached to the transevaporator by
a pre-shrunk PTFE sleeve (sample end down). The remainder of the
apparatus is assembled with a water-cooled micro-condenser
included between the transevaporator and the Porasil E micro-column.
The modified headspace sample is then collected by attaching a
Tenax trap to the transevaporator using either a ground-glass joint
or a shrinkable PTFE sleeve. The sample transfer is effected by
passing helium at a flow-rate of 16 ml min-1
 through the apparatus
for 5-10 mina. The Tenax tube is then removed and stored at -100C
in a screw-capped PTFE-lined culture tube until analysed. The
elution micro-column is removed and attached to a second trans-
evaporator without a condenser. The extraction profile is collec-
ted on a glass bead column attached to the transevaporator. For
extraction, 0.5-1.0 ml of solvent (pentane, diethyl ether, 2-
ch,loropropane) is added by syringe to the conical tip of the
centrifuge tube, and the apparatus reassembled. The helium carrier
gas was switched on and adjusted to a flow rate of 0.5 m1 min-1
or less so that the solvent travelled slowly up the Porasil E
column (1-2 min) and was eventually transferred entirely to the
glass bead column. The elution micro-column is then removed, the
apparatus reassembled and the helium flow rate increased to 16
ml min-1 to remove excess of solvent (5-10 min). The organic
volatiles trapped on either Tenax or glass beads are thermally
desorbed in a desorption chamber maintained at 280 0  by purging
with helium at 7 ml min-1
 for 10 min. The volatiles are trapped
in a U-shaped stainless steel, precolumn (30 cm x 1.0 mm i.d.)
coated with the same stationary phase as used for the analytical
column and immersed in a liquid nitrogen Dewar flask. The pre
5column is attached to the analytical column (first) via a
Swagelock fitting, , connected to the carrier gas inlet (injector)
by a second fitting, a carrier gas flow rate of 2-5 ml min -I
established and the liquid nitrogen trap removed. When the in-
side diameter of the precolumn was greater than that of the ana-
lytical column, the sample was transferred to a second 15-cm
precolumn of the same inside diameter as the analytical column
by immersing the second precolumn in a liquid nitrogen Dewar
flask and heating the first to 2000C with a small electrical
current from a d.c. power supply or by use of a heat gun. When
the analytical column is made of metal, the first 15 cm of it
can be wound into a spiral and used as the second precolumn To
start the analysis, the liquid nitrogen Dewar flask was removed
and the temperature program initiated.
The organic volatile fraction was separated on either a nickel
capillary column (100 m x 0.25 mm i.d.) coated with Witconol LA-23,
or with a 106 m x 0.25 mm i.d. glass column coated with tSilar IOC.
The sampling procedure is designed to be independent of the gas
chromatograph used and any gas chromatograph that is compatible
with the use of capillary columns can be used for the analysis.
DATA HANDLING
As a result of the complexity of the organic volatile fraction
and problems associated with collecting and evaluating the chroma-
tographic data, a computing integrator is needed to assemble the
chromatographic information in a machine readable form. The chroma-
tographic data base is assembled with dimensions of absolute reten-
tion time as a descriptor for peak identification and peak area as
a descriptor for concentration. Different chromatograms are com-
x	 Y
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pared using this data base. When there is a consistent large
change in the area of a few peaks in the chromatogram of the
organic volatiles obtained from a pathological sample, compared
with their mean average peak area in normal samples, then visual
inspection of the chromatogram usually suffices for clinical
diagnostic purposes. But there are exceptions, when a more
sophisticated procedure, computer- aided pattern-recognition, is
required. Reliable visual comparison of large numbe y,t of profiles,
containing more than 200 peaks, obviously is not feasible. Tech-
niques involve the use of clinically defined samples to provide
training sets, which are used to establish pattern vectors charac-
teristic of the sample type. These pattern vectors are then used
to classify a further set of samples, not used 'n the training
set, to test the efficiency of the pattern-re!,:ognition algorithm.
The K-nearest-neighbor-pattern recognition procedure was used
throughout the work described in this report. A full description
of the programs and operations has been detailed elsewhere (32)..
RESULTS
The transevaporator sampling technique was developed out of
a series of experimental improvements in the micro-solvent extrac-
tion method. Removal of the extraction solvent by syringe was
inconvenient and the first transevaporator was designed for this
purpose. The base was the extraction tube and a narrow-bore tube
extended from the glass-wool trap to just above the
interface. Helium carrier gas was used to transfer
layer to the glass-wool trap and then to strip away
solvent. At room temperature, ether extracts about
water, which can cause problems at the desorption s'
ether-sample
the ether
the ether
7% v/v of
tage by
7blocking the precolumn. To retain the water and also to distribute
the sample uniformly over a .large surface area, the biological
fluid was injected into a micro-column packed With Porasil E and
the extraction solvent forced through the column by gas pressure.
The micro-column retains most of the water and the high relative
molecular nass polar organics and inorganic salts present in the
biological fluids.
The transevaporator is able to provide two profiles, a modi-
fied headspace and a solvent elution profile in a sequential manner
from the same sample. The modified headspace profile contains very
few peaks and i5 of little value for diagnostic purposes compared
with the solvent elution profile.
As an analytical tool, the transevaporator sampling apparatus
is a. semi-quantitative technique capable of providing reproducible
organic volatile profiles from biological fluids. In absolute
terms, the percentage recovery of test compounds depends on both
the volatility and the chemical nature of the compounds being
studied. For aqueous standards containing propan-1-o1, butan-1-ol,
decan-2-one, heptan-2-one, and benzaldehyde prepared to cover the
range 0.5-5.0 ppm, the percentage recovery was consistent for each
compound throughout the concentration range and averaged 20, 40,
50, 55, and 70%, respectively, for the test compounds. The repro-
ducibility of the solvent extraction profile obtained from 50 ul
of a pooled normal serum sample is illustrated In Figure 4 for three
separate replicate analyses.
The chromatograms in Figure 4 also indicate the complexity of
the organic volatile fraction from serum. The intercomparison of
chromatograms requires the use of pattern recognition techniques
uand computer interpretation to handle the immense amount of infor-
mation generated in a screening program.
To make the data compatible between chromatogram`, a fixed
volume of sample is extracted for each analysis and the peak areas
are normalised after elimination of background peaks and of odd
peaks that appear in only a, few chromatograms. The success of the
sampling technique as a diagnostic aid is very dependent on the
reproducibility of the profile obtained. For the pooled normal,
serum (10 replicate analyses), the median average t;el,ative standard
deviation was 18.3% and the range 6.5-51.1%. Retention times can
be reproduced to better than 1% relative standard deviation in the
chromatographic system. These results are typical of other biolo-
gical fluids and illustrate the reproducibility that can be expec-
ted when using the transevaporator sampling technique. Another
important parameter in profiling techniques is the biochemical
individuality of the human population. For 15 serum samples ob-
tained from bealthy individuals, the median average relative stan-
dard deviation was 32.9% and the ,range 17.1-87.5% for the selected
chromatographic peaks used to provide the data base for comparison
with patient's serum. The data base consisted of approximately
150 detected peaks, of which about 75 were detected in all 15 serum
samples and used for the calculation. The biochemical individual``^y
is much more suppressed in serum than in urine, making the compari-
son of different profiles less troublesome. For diagnostic purr
poses, the consistent change in concentration of a peak or peaks
greater than one relative standard deviation of the value obtained
for the normal profiles is considered significant and used for the
detection of the disease.
INVESTIGATION INTO SAMPLING METHODS
A serieo of mthods are user by different surgeions to obtain
serum samples. The possibility of contamination of the sample or
loss of components from the sample due to the sampling method tzas
statistically evaluated using three human male volunteers. The
methods of obtaining the serum satiples were as follows:
(a) all glass system us,tng ,%n aluminum needle; glass syringe,
glass centrifuge tubes, glass vial (no plastic or rubber)
(b) glass vacutainer with rubber stopper, glass centrifuge
tubes and glass vials
(c) as in (b) but heparin added to blood prior to centrifuge
step
(d) blood drawn by a pedi-Butterfly apparatus through a
polyethylene tube to a plastic syrin ,.°e, glass centrifuge
tube, glass vial.
Method (a) was certainly the method of choice. The extraneous
background contribution to the chromatogram was minimized and no
major contami.nanats were observed. Method (c) gave the worst
results. The use of heparin to aid precipitation of the red blood
cells can not be recommended. Several major contaminant peaks
were observed. Methods (b) and (d) were intermediate between (a)
and (c). Some contamination of the sample was observed compared
to serum samples obtained by method (a). This background contri-
bution was variable but in most cases statistically not unaccep-
table. No major contaminants were found. Methods (b) and (d)
were deemed to be acceptable but not preferable. Method (a)
using an all glass-aluminum system is highly recommended and
F
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should be used whenever possible.
The loss of organic volatile* from the serum samples obtained
by methods (a) to (c) was not significant. Relative concentrations
of normal components (excluding contaminants) remained within the
experimentally defined limits of the reproducibility of the analy-
tical system.
SERUM FROM VIRUS INFECTED MICE
Ten serum samples were collected from mice as follows: 1-3
are normal serum samples, 4-7 are serum samples from virus infected
mace, and 8-10 are serum samples from mice after a convalescent
period (i.e., 17 days after virus infecAson).
A visual inspection was made of all peaks in she chromatograms
from mice 1-10. EAJI, )teen peaks were identified as being present in
all serum samples and were absent in the blank. The eighteen peak
data set was nomalized and the relative standard dev.,atior, calcu-
lated for the normal mouse serum samples 1-3 (Table 1). This data
was used to assign experimental and normal variations for the data
set and when compared with the values in the virus infected mouse
sera, only peaks different by at least one standard deviation from
the normal values were considered significant. The relative stan-
dard deviation for the peaks covered the range 1-58% which is
typical for the transevaporator. The mean relative standard devia-
tion was 18% which is excellent if one considers the complexity of
the sample and the trace level (ppm to rpb) levels being determined.
The eighte"n peak data set was determined for the four mice
(4-7) which were infected with virus. One sample was highly con-
taminated and was eliminated from the data set. The individual
values for 4, 6, and 7 are summarized in Table 2. A comparison
n
of Tables 1 and 2 indicates that psi
elevated above the normal value upon
11
Serum satisIes were obtained from 8, 9, and 10, seventeen
days after infection. It was assumed that the mice would have
completely recovered from the infection. The individual values
are summarized in Table 3. For each mouse, the normalezed peak
area for peaks 14 and 15 has declined from the infected value but
has not reached the averaged normal serum concentration of these
peaks.
The data obtained in this study is highly predictive as the
virus infected mice were easily distinguished form the normal mace
samples,
SCRUM FROM VIRUS XNFRCTRD HUMANS
Ten serum samples obtained from human volunteers were chroma-
tographed and twenty-six
 peaks identified as being present in all
serum samples and absent in the blank. The samples available
included 5 normal serum samples, 4 virus infected serum samples
(6-9), and one convalescent serum sample (10). The twenty -six
peak data set was normalized and the relative standard deviation
calculated for the five normal serum samples (Table 4). The
relative standard deviation for the selected peaks covered the
range 9-65% with a mean value of 28%. The normalized peak areas
for the virus infected serum samples are given in Table 5. Peaks
6, 12, 13, and 25 were found to vary significantly in concentration
(the difference ineak area wasp	 greater than one standard devia-
tion). Peaks 6, 12, and 25 were lowered in concentration while
peak 13 was elevated in concentration. The normalized peak areas i
for the convalescent strum sample are given in Table 6. For this
`yn
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sample, the serum values of peaks 6 1 12, 13, and 25 have not
returned to their normal values, The results obtained in this
study are in keeping with our previous preliminary study which
adds to the confidence of the general predictive value of this
technique for assessing virus infection.
CONCLUSl4NS
The transevaporator sampling apparatus developed for the
isolation of the organic volatilo fraction of serum samples from
mice or humans prior to their separation by high-resolution gas
chromatography, has a small sample requirement of 5-500 pl, and
is ideally suited to profiling studies of serum for the identifi-
cation of chemical markers of value as a diagnostic aid for the
recognition of upper respiratory virus infection. During the
project permed, a total of 46 human serum and 10 mice samples
were analyzed and several diagnostic pears identified which were
characteristic of the virus infected state. Using pattern recog-
nition techniques, 87% of the samples were successfully charac-
terized as virus infected or normal after the training algorithm
had been developed.
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TABLE 1. 18 PEAK DATA SET FOR ORGANIC VOLATILES IN NORMAL
MOUSE SERUM MICE Nos, 1-3)
Peak Identification Mean Normalized Standard Relative Standard
Number Area Deviation Deviation ^)
1 3.79 0.21 5.5
2 32.57 2.36 7.3
3 5.62 0.71 12.6
4 1.93 0.46 23.9
5 4.97 0.50 10.9
6 13.16 0.19 1.4
7 3.75 0.90 24.0
8 0.98 0.38 38.9
9
10 1.11 0.64 57.9
11 2.02 0.22 10.6
12 2.00 0.66 32.8
13 10.01 0.98 9.8
14 3.74 0.34 9.0
15 1.54 0.04 2.9
16 3.55 1.65 46.5
17 6.38 0.79 12.4
18 2.34 0.31 13.4
t	 ^
TABLE 2. 18 PEAK DATA SET FOR VIRUS INFECTED MICE (Nos. 4, 6, 7)
Peak Identification NORMALIZED PEAK AREA
Number Mouse 4 Mouse 6 Mouse 7
1 3.88 3.44 1.58
2 37.35 29.94 27.76
3 5.47 4.24 3.49
4 1.61 2.23 1.73
5 6.37 5.42' 5.74
6 14.02 13.82 13.09
7 3.02 4.29 2.99
8 0.61 1.49 1.13
9 0.70 1.24 1.12
10 0.90 1.05 1.10
11 2.05 2.53 2.76
12 2.11 2.26 2.04
13 8.55 10.50 12.21
14 4.39 4.97 5.23
15 1.98 1.92 2.76
16 3.53 4.65 5.89
17 2.41 4.67 7.26
18 1.06 1.83 2.07
LTABLE 3. 18 PEAK DATA SET FOR CONVALESCENT MICE (Nos. 8, 9, 10)
Peak Identification
Number
1
2
3
4
5
6
7
8
9
10
12
13
14
15
16
17
18
NORMALIZED PEAK AREA
Mouse 8 Mouse 9
2.39 4.52
24.57 28.36
4.29 5.30
1.57 1.38
4.12 4.37
14.83 14.37
3.80 4.55
1.66 0.94
1.18 0.55
0.96 1.30
2.91 1.99
1.56 2.29
12.81 12.42
4.10 1.86
1.95 1.35
6.64 3.06
7.65 8.19
,3.00 2.90
Mouse 10
3.10
34.26
5.59
1.43
5.09
14.40
3.64
1.40
0.62
1.02
1.57
1.85
10.37
3.46
1.75
2.78
4.87
2.48
i
'st
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TABLE 4.
	
26 PEAK DATA SET FOR ORGANIC VOLATILES IN NORMAL, HUMAN SERUM
Peak Identification Retention Time Mean Normalized Standard Relative Standard
Plumber Minutes Area Deviation Deviation M
1 19.43 3.68 0.93 25.2
4	 2 20.34 9.14 2.99 32.2
3 20.63 8.73 4.55 52.1
4 23.44 10.38 2.76 26.6
5 28.19 2.54 0.36 14.3
6 28.58 7.26 0.92 12.6
7 29.13 5.54 0.50 9.1
8 32.56 2.29 0.68 29.9
9 33.31 1.28 0.40 31.3
14 33.55 1.36 0.34 25.0
k.
	11 37.03 5.76 0.98 17-1
12 37.48 2.27 0.30 13.2
13 39.60 3.08 0.57 25.2
14 40.59 6.24 0.80 28.8
r
15 42.70 2.84 2.12 34.0
16 43.17 6.39 0.90 31.6
i	 17 44.75 2.62 0.63 10.7
18 48.54 2.99 1.02 25.8
i
19 50.77 1.51 0.36 34.0
20 51.15 Z.52 0.69 23.9
k	
`:	 21 53.06 2.29 1.49 27.3
r	 22 53.46 1.57 0.33 65.2
23 56.68 1.24 0.53 2018
24 58.74 1.24 0.53 42.9
25 23.95 3.14 1-.46 46.1
26 24.11 1.80 0.59 35.9
TABLE 5. 26 PEAK DATA SET FOR VIRUS INFECTED HUMAN SERUM
VOLUNTEER NUMBER
Peak Identification
Number	 NORMACIZED AREAS......
1 3.32 3.40
2 10.38 12.76
3 13.18 14.54
4 14.20 11.75
5 2.01 2.52
6 6.03 5.29
7 4.76 5.77
8 1.10 4.06
9 1.00 1.68
10 1.27 1.89
11 6.17 4.97
12 1.61
13 2.90 3.54
14 1.72 1.50
r	 15 3.97 7.06
16 3.39 2.11
i	 17 6.49 5.62
18 1.98 1.68
19 1.34 1.27
20 1.33
!	 21 1.52 4.02
22 4.23
23 2.10 1.69
24 0.82
25 1.45 1.62
26 1.14 1.33
3.42
7.95
11.06
20.16
2.18
5.30
4.20
4.87
1.86
1.98
4.15
1.45
4.75
2.03
5.08
1.66
5.28
1.57
2.01
0.85
1.21
0.83
2.65
0.83
1.30
1.37
3.37
11.03
11.96
13,45
2.78
5.82
5.14
1.94
2.14
1.91
3,93
1.21
3.46
2.18
7.12
1.66
5.40
2.26
3.78
1.06
1.47
3.36
1.84
0.90
1.26
1.28
I
*peak areas less than the integrator threshold value
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3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
TAB ► E 6. 26 PEAK DATA SET FOR A CONVALESCENT SERUM SAMPLE
Peak Identification Number
	
Normalized Peak Area.,
3.34
7.77
10.81
19.70
2.13
5.18
4.11
4.76
1.82
1.94
4.05
1.41
4.64
1.98
4.97
1.62
7.44
1.53
1.96
0.83
1.18
0.81
2.59
0.81
1.27
1.33
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figure 4. Repeatability of the transevaporator sampling
technique in the solvent elution mode for three
50 pl samples of a pooled normal serum. The
three replicate separations were performed on a
106 m x 0.25 mm i.d4 glass capillary column
coated with Silar IOC, The column was programmed
with an initial isothermal periol at 40 0C for 6
min, then programmed at 20C min- to 1800C and
held at this temperature for 30 min ., Helium
carrier gas flow rate, 1.5 ml min-1.
